Trials / Completed
CompletedNCT04567615
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 266 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
| BIOLOGICAL | Relatlimab | Specified dose on specified days |
Timeline
- Start date
- 2021-02-04
- Primary completion
- 2023-08-31
- Completion
- 2025-11-19
- First posted
- 2020-09-28
- Last updated
- 2026-01-08
- Results posted
- 2024-10-08
Locations
65 sites across 17 countries: Argentina, Brazil, Chile, China, Czechia, France, Hong Kong, Japan, Mexico, New Zealand, Poland, Romania, Singapore, South Korea, Spain, Taiwan, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04567615. Inclusion in this directory is not an endorsement.